NADMED
The Helsinki-based company developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours to detect vitamin B3 deficiencies and prevent disease.
Helsinki, Finlandwww.nadmed.com ↗
Total raised
€3.5M
€3,500,000
Funding rounds
1
Investors
5
distinct backers
Active since
2024-08
latest 2024-08
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood33
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-08-22 | Other | €3.5M | Business Finland,Nordic Science Investments (NSI),private European investors,University of Helsinki Funds,Voima Ventures | View deal → |
Investors
5Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Iceye€1.5BFinland · Space
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Nokia€859MFinland · Telecom